secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001193125-24-142232
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne: DYNE-101 achieves 27% splicing correction at 3 months; DYNE-251 shows 3.22% dystrophin expression in DMD
--------------------------------------------------------------------------------

- DYNE-101 5.4 mg/kg Q8W showed 27% mean splicing correction across 22-gene panel at 3 months, all participants responded.
- DYNE-101 improved myotonia (vHOT) by 4.5 sec at 3 months (5.4 mg/kg) and 4.4 sec at 12 months (1.8 mg/kg Q4W).
- DYNE-251 10 mg/kg monthly achieved mean unadjusted dystrophin 3.22% (7.64% muscle-adjusted) vs 0.30% for weekly eteplirsen.
- DYNE-251 showed trends in functional endpoints: NSAA, SV95C, 10-Meter Walk/Run, and Time to Rise at 6 months.
- Favorable safety for both; FDA accelerated approval pathways confirmed; registration pathway update expected by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524142232/0001193125-24-142232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524142232/d821973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-142232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer